Debiopharm S.A., the independent drug development company specialising in oncology, endocrinology and niche products, along with its wholly owned investment affiliate, Debioinnovation, and Neovacs S.A., a French biotechnology company specializing in the development of proprietary anti-cytokine immunogens, today announced the signature of a license and equity agreement for the development of a TNF (tumour necrosis factor) alpha kinoid® and its related technology programmes.

Neovacs, biotechnology firm and leader in antibody therapies, has just named Jean-Jacques Bertrand as its Chairman. “I am proud to pass the baton to Jean-Jacques Bertrand, former Chairman of Aventis Pasteur and member of the “CEO Circle” of Truffle Venture” declared Dr Philippe Pouletty, previous Chairman of Neovacs who remains one of its directors.

Neovacs, a French biotechnology company leader in therapeutic polyclonal antibodies, receives the IVCS prize in the Life Sciences category. The 8 th IVCS rewarded 4 companies in the following strategic fields: Life Sciences, Energy, Microelectronics, Information Technology and Software and Multimedia. The IVCS is one of the key European conferences related to the financing of European most innovative companies...

Neovacs, leader in the next generation of antibody therapies, today announced that it has raised €1.5 million and simultaneously has obtained a €1.2 million grant. Parisbased Truffle Venture FCPR and Europe Innovation FCPI, current Neovacs investors, invested an additional €1.5 million in convertible bonds. At the same time Neovacs was granted €1.2 million from ANVAR, the French Agency for Innovation, for the development of Neovacs’ anti-TNF program. Truffle Venture thus reaffirms

Neovacs, a spin-off biotechnology company from Pierre and Marie Curie University and the leader in the development of vaccine-induced polyclonal antibody therapies, today announced that it has raised 3.5 million Euros in new financing. Paris-based Truffle Venture FCPR and Europe Innovation FCPI made the investment, and now own 51% of Neovacs. Neovacs currently develops several promising product candidates based on its cytokine vaccine and viral vaccine patented technologies. Neovacs therapeutic AIDS vaccine is already in human clinical trials in collaboration with Aventis Pasteur. Aventis Pasteur, the vaccines business of Aventis, is one of the world’s largest vaccine producers. Neovacs also acquired from...